Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.77 |
| ▸ | KIT | P10721 | 4/20 | 0.77 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.77 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.77 |
| ▸ | ABL2 | P42684 | 2/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.77 |
| ▸ | MLNR | O43193 | 1/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.77 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011304 | 1.00 | ABL1 (1.00) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL24123124 | 0.95 | ABL1 (1.00) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL13194694 | 0.91 | ABL1 (0.88) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL12989619 | 0.90 | ABL1 (1.00) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL589689 | 0.90 | ABL1 (1.00) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL15242137 | 0.89 | ABL1 (0.85) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL21367370 | 0.89 | ABL1 (0.85) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL15473029 | 0.88 | ABL1 (0.83) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL10207526 | 0.87 | ABL1 (0.78) | ABL1CYP3A4KCNH2KITDDR1 | |
| SCHEMBL18304587 | 0.87 | ABL1 (0.77) | ABL1CYP3A4KCNH2KITDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | SMN1; SMN2, MCL1, NLN | ABL1 76/4885CYP3A4 2737/4885KCNH2 2222/4885 |
| US-20210393628-A1 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | CD4, ICOS, NFATC1 | ABL1 237/4885CYP3A4 2204/4885KCNH2 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.